T-Cell Receptor Therapy for Synovial Sarcoma

Cleveland Clinic has announced that a novel T-cell receptor therapy is now available for a specific segment of patients diagnosed with synovial sarcoma, marking a significant advancement in the treatment of this rare soft tissue cancer. The therapy, which engineers a patient’s own immune cells to target cancer-specific antigens, is being offered through the hospital’s sarcoma program and is currently accessible to individuals whose tumors express the MAGE-A4 antigen, a protein found in a subset of synovial sarcoma cases.

The treatment, known as afamitresgene autoleucel (formerly called AFB-101), is an autologous T-cell receptor gene therapy developed by Affimed N.V. In collaboration with other research partners. It works by extracting T cells from a patient’s blood, genetically modifying them to recognize the MAGE-A4 protein present on cancer cells, and then infusing the enhanced cells back into the patient to stimulate an immune response against the tumor. This approach represents a form of personalized immunotherapy designed to treat solid tumors that have historically been difficult to target with conventional therapies.

According to Cleveland Clinic, eligibility for the therapy is determined through biomarker testing to confirm MAGE-A4 expression in the tumor tissue. Only patients whose synovial sarcoma tests positive for this antigen are considered candidates for the treatment. The clinic emphasized that not all synovial sarcoma patients express MAGE-A4, and the therapy is therefore intended for a defined molecular subset of the disease population.

The availability of afamitresgene autoleucel at Cleveland Clinic follows positive results from earlier-phase clinical trials, including data presented at major oncology conferences showing tumor reduction in a portion of treated patients with metastatic or unresectable synovial sarcoma. The U.S. Food and Drug Administration has granted the therapy both Fast Track and Orphan Drug designations, reflecting its potential to address an unmet medical need in a rare cancer indication.

We are proud to offer this innovative therapy to eligible patients with synovial sarcoma, providing a new option where traditional treatments have limited effectiveness,” said Dr. Seth Pollack, Director of the Sarcoma Program at Cleveland Clinic. “By targeting MAGE-A4, we are able to harness the immune system to attack cancer cells with greater precision, offering hope to patients who have exhausted other avenues.”

Dr. Seth Pollack, Cleveland Clinic

Synovial sarcoma is a rare malignant tumor that typically arises in the soft tissues near joints, most commonly in adolescents and young adults. While surgery, radiation, and chemotherapy remain standard treatments, outcomes for advanced or recurrent cases have historically been poor, with limited therapeutic options available. The introduction of antigen-targeted T-cell therapies like afamitresgene autoleucel represents a shift toward precision immunotherapy in sarcoma oncology.

Affimed N.V., the biotechnology company behind the therapy, has reported ongoing clinical development of afamitresgene autoleucel not only for synovial sarcoma but also for other solid tumors expressing MAGE-A4, including certain head and neck and non-small cell lung cancers. The company has partnered with institutional research centers to expand access and gather real-world data on safety and efficacy outside of clinical trial settings.

Cleveland Clinic’s sarcoma program, recognized as a national leader in the diagnosis and treatment of bone and soft tissue sarcomas, integrates multidisciplinary care with access to cutting-edge clinical trials and emerging therapies. The institution’s adoption of afamitresgene autoleucel underscores its role as an early adopter of novel immunotherapies in rare cancers, particularly those with identifiable molecular targets.

Patients interested in the therapy must undergo a comprehensive evaluation at Cleveland Clinic, including imaging, biopsy, and molecular profiling, to determine eligibility. Treatment involves leukapheresis to collect T cells, laboratory modification, lymphodepleting chemotherapy to prepare the body, and infusion of the engineered cells, followed by close monitoring for side effects such as cytokine release syndrome or neurotoxicity, which are known risks associated with T-cell engaging therapies.

As of now, afamitresgene autoleucel is not yet broadly approved by the FDA for commercial use, but its availability at Cleveland Clinic is being administered under investigational protocols or expanded access pathways, consistent with its status as an emerging therapy. The clinic advises that access may vary based on clinical trial enrollment, institutional review board approvals, and individual patient suitability.

The introduction of this therapy reflects a broader trend in oncology toward leveraging genomic and immunologic insights to develop treatments for rare and aggressive cancers. By focusing on specific molecular markers like MAGE-A4, researchers aim to improve response rates and reduce exposure to ineffective therapies, advancing the promise of precision medicine in sarcoma care.